Search Results - "Adair, Sara J"

Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth by Nagdas, Sarbajeet, Kashatus, Jennifer A., Nascimento, Aldo, Hussain, Syed S., Trainor, Riley E., Pollock, Sarah R., Adair, Sara J., Michaels, Alex D., Sesaki, Hiromi, Stelow, Edward B., Bauer, Todd W., Kashatus, David F.

“…Mitochondria undergo fission and fusion to maintain homeostasis, and tumors exhibit the dysregulation of mitochondrial dynamics. We recently demonstrated that…”
Get full text

CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response by Szlachta, Karol, Kuscu, Cem, Tufan, Turan, Adair, Sara J., Shang, Stephen, Michaels, Alex D., Mullen, Matthew G., Fischer, Natasha Lopes, Yang, Jiekun, Liu, Limin, Trivedi, Prasad, Stelow, Edward B., Stukenberg, P. Todd, Parsons, J. Thomas, Bauer, Todd W., Adli, Mazhar

“…Predicting the response and identifying additional targets that will improve the efficacy of chemotherapy is a major goal in cancer research. Through…”
Get full text

Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens by Walters, Dustin M, Stokes, Jayme B, Adair, Sara J, Stelow, Edward B, Borgman, Cheryl A, Lowrey, Bryce T, Xin, Wenjun, Blais, Edik M, Lee, Jae K, Papin, Jason A, Parsons, J Thomas, Bauer, Todd W

“…Relevant preclinical models that recapitulate the key features of human pancreatic ductal adenocarcinoma (PDAC) are needed in order to provide biologically…”
Get full text

Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib by Walters, Dustin M, Lindberg, James M, Adair, Sara J, Newhook, Timothy E, Cowan, Catharine R, Stokes, Jayme B, Borgman, Cheryl A, Stelow, Edward B, Lowrey, Bryce T, Chopivsky, Maria E, Gilmer, Tona M, Parsons, John T, Bauer, Todd W

“…Abstract Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor receptor (EGFR) and human…”
Get full text

A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest by Newhook, Timothy E, Blais, Edik M, Lindberg, James M, Adair, Sara J, Xin, Wenjun, Lee, Jae K, Papin, Jason A, Parsons, J Thomas, Bauer, Todd W

“…Currently, prognostication for pancreatic ductal adenocarcinoma (PDAC) is based upon a coarse clinical staging system. Thus, more accurate prognostic tests are…”
Get full text

Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates by Mandal, Arabinda, Shetty, Jagathpala, Tran, Christine A, Olson, Walter C, Mandal, Mriganka, Ban, Bhupal, Pires, Eusebio S, Adair, Sara J, Bauer, Todd W, Slingluff, Craig L, Herr, John C

“…Background Sperm acrosomal SLLP1 binding (SAS1B) protein is found in oocytes, which is necessary for sperm-oocyte interaction, and also in uterine and…”
Get full text

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer by Lindberg, James M, Newhook, Timothy E, Adair, Sara J, Walters, Dustin M, Kim, Alison J, Stelow, Edward B, Parsons, J. Thomas, Bauer, Todd W

“…Abstract Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutations and epidermal growth factor receptor (EGFR) family signaling are drivers of…”
Get full text

Automated biophysical classification of apoptotic pancreatic cancer cell subpopulations by using machine learning approaches with impedance cytometry by Honrado, Carlos, Salahi, Armita, Adair, Sara J, Moore, John H, Bauer, Todd W, Swami, Nathan S

“…Unrestricted cell death can lead to an immunosuppressive tumor microenvironment, with dysregulated apoptotic signaling that causes resistance of pancreatic…”
Get more information

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells by Wei, Xiaolong, Yang, Jiekun, Adair, Sara J., Ozturk, Harun, Kuscu, Cem, Lee, Kyung Yong, Kane, William J., O’Hara, Patrick E., Liu, Denis, Demirlenk, Yusuf Mert, Habieb, Alaa Hamdi, Yilmaz, Ebru, Dutta, Anindya, Bauer, Todd W., Adli, Mazhar

“…Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat. Due to the asymptomatic nature of the disease and lack of…”
Get full text

Neural Network-Enabled Multiparametric Impedance Signal Templating for High throughput Single-Cell Deformability Cytometry Under Viscoelastic Extensional Flows by Jarmoshti, Javad, Siddique, Abdullah-Bin, Rane, Aditya, Mirhosseini, Shaghayegh, Adair, Sara J, Bauer, Todd W, Caselli, Federica, Swami, Nathan S

“…Cellular biophysical metrics exhibit systematic alterations during processes, such as metastasis and immune cell activation, which can be used to identify and…”
Get full text

CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer by Michaels, Alex D, Newhook, Timothy E, Adair, Sara J, Morioka, Sho, Goudreau, Bernadette J, Nagdas, Sarbajeet, Mullen, Matthew G, Persily, Jesse B, Bullock, Timothy N J, Slingluff, Jr, Craig L, Ravichandran, Kodi S, Parsons, J Thomas, Bauer, Todd W

“…Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and adjuvant chemotherapy have an expected survival of only 2 years due to…”
Get full text

Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment by Stokes, Jayme B, Adair, Sara J, Slack-Davis, Jill K, Walters, Dustin M, Tilghman, Robert W, Hershey, E Dan, Lowrey, Bryce, Thomas, Keena S, Bouton, Amy H, Hwang, Rosa F, Stelow, Edward B, Parsons, J Thomas, Bauer, Todd W

“…Current therapies for pancreatic ductal adenocarcinoma (PDA) target individual tumor cells. Focal adhesion kinase (FAK) is activated in PDA, and levels are…”
Get full text

Survival benefit associated with screening of patients at elevated risk for pancreatic cancer by Kane, William J., Haden, Kathleen R., Martin, Elizabeth N., Shami, Vanessa M., Wang, Andrew Y., Strand, Daniel S., Adair, Sara J., Nagdas, Sarbajeet, Tsung, Allan, Zaydfudim, Victor M., Adams, Reid B., Bauer, Todd W.

“…Background & Objectives Screening for pancreatic cancer is recommended for individuals with a strong family history, certain genetic syndromes, or a neoplastic…”
Get full text

A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreatic cancer by Brown, Brooke A, Myers, Paul J, Adair, Sara J, Pitarresi, Jason R, Sah-Teli, Shiv K, Campbell, Logan A, Hart, William S, Barbeau, Michelle C, Leong, Kelsey, Seyler, Nicholas, Kane, William, Lee, Kyoung Eun, Stelow, Edward, Jones, Marieke, Simon, M Celeste, Koivunen, Peppi, Bauer, Todd W, Stanger, Ben Z, Lazzara, Matthew J

“…The tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) plays a key role in tumor progression and response to therapy. The dense PDAC stroma…”
Get full text

Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules by Adair, Sara J, Hogan, Kevin T

“…Purpose To test the hypothesis that decrease in DNA methylation will increase the expression of cancer-testis antigens (CTA) and class I major…”
Get full text

ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer by Ozturk, Harun, Cingoz, Harun, Tufan, Turan, Yang, Jiekun, Adair, Sara J., Tummala, Krishna Seshu, Kuscu, Cem, Kinali, Meric, Comertpay, Gamze, Nagdas, Sarbajeet, Goudreau, Bernadette J., Luleyap, Husnu Umit, Bingul, Yagmur, Ware, Timothy B., Hwang, William L., Hsu, Ku-lung, Kashatus, David F., Ting, David T., Chandel, Navdeep S., Bardeesy, Nabeel, Bauer, Todd W., Adli, Mazhar

“…Pancreatic ductal adenocarcinoma (PDA) cells reprogram their transcriptional and metabolic programs to survive the nutrient-poor tumor microenvironment…”
Get full text

Apoptotic Bodies in the Pancreatic Tumor Cell Culture Media Enable Label‐Free Drug Sensitivity Assessment by Impedance Cytometry by Honrado, Carlos, Adair, Sara J., Moore, John H., Salahi, Armita, Bauer, Todd W., Swami, Nathan S.

“…The ability to rapidly and sensitively predict drug response and toxicity using in vitro models of patient‐derived tumors is essential for assessing…”
Get full text

Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis by Newhook, Timothy E., Lindberg, James M., Adair, Sara J., Kim, Alison J., Stelow, Edward B., Rahma, Osama E., Parsons, J. Thomas, Bauer, Todd W.

“…Purpose Most patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of…”
Get full text

Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer by Knapp, Kiley A, Pires, Eusebio S, Adair, Sara J, Mandal, Arabinda, Mills, Anne M, Olson, Walter C, Slingluff, Jr, Craig L, Parsons, J Thomas, Bauer, Todd W, Bullock, Timothy N, Herr, John C

“…Successful therapeutic options remain elusive for pancreatic cancer. The exquisite sensitivity and specificity of humoral and cellular immunity may provide…”
Get full text

Immunological profiling of a panel of human ovarian cancer cell lines by Carr, Tiffany M., Adair, Sara J., Fink, Mitsú J., Hogan, Kevin T.

“…Purpose The efficient identification of peptide antigens recognized by ovarian cancer-specific cytotoxic T lymphocytes (CTL) requires the use of…”
Get full text